This study was conducted to determine the rate of detection of serum hepatitis B virus (HBV) DNA in hepatitis B surface antigen (HBsAg)-negative decompensated cirrhotic patients who had hepatitis B core a n d or surface antibodies (anti-HBc andor anti-HBs), and to compare the outcome of HBsAg-positi
Characterization of two hepatitis B virus populations isolated from a hepatitis B surface antigen–negative patient
✍ Scribed by Damien Jeantet; Isabelle Chemin; Bernard Mandrand; Fabien Zoulim; Christian Trepo; Alan Kay
- Book ID
- 111721827
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 348 KB
- Volume
- 35
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ؍ 60
## Abstract Sera from 20 Chinese patients with chronic hepatitis B were examined for hepatitis B e antigen and hepatitis B virus (HBV) DNA. There was considerable discordance with HBV DNA not being detectable in 10 out of 13 (77%) patients who were hepatitis B e antigen positive. Further testing fo
ne response to the shortage of cadaver organs 0 has been to evaluate donors previously not considered suitable. One group consists of donors who are hepatitis B surface antigen-negative (HBsAg[ -1) and hepatitis B core antibody-positive (HBcAb[+]). We present a case report of an individual receiving